Form 4: Recursion Pharmaceuticals CEO Executes Tax Withholding

CEO Najat Khan disposed of 62,701 shares of Recursion Pharmaceuticals to satisfy tax obligations related to restricted stock units.

Summary

• Najat Khan, CEO and President of Recursion Pharmaceuticals, Inc. (RXRX), reported the disposition of 62,701 shares of Class A Common Stock.
• The transaction occurred on May 15, 2026, at a price of $3.04 per share.
• The shares were withheld by the company to satisfy tax withholding and remittance obligations associated with the net settlement of restricted stock units.
• Following this transaction, the reporting person maintains beneficial ownership of 2,199,384 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the share disposition is purely administrative and related to tax compliance rather than a strategic divestment.

Positives

• The transaction is a routine administrative action related to tax obligations rather than a discretionary market sale.

Negatives

• The reduction in total shares held by the CEO may be viewed as a minor decrease in direct equity stake.

Risks

• Market volatility affecting the valuation of equity-based compensation.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that net settlement of restricted stock units is a standard industry practice for executives to manage tax liabilities arising from the vesting of equity awards, and does not typically signal a change in management sentiment regarding company performance.

Comparison to Industry Standards

• The transaction aligns with standard corporate governance practices for executive compensation tax management in the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a standard tax-related settlement.

Key Dates

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Najat Khan, Biotech, Equity Compensation